Founded in 2005, Korea Institute for Pharmaceutical Policy Affairs, KIPPA, is a non-profit, public foundation, approved by the Korean Ministry of Health and Welfare. The institute is contributed by three relevant parties, the Korean Pharmaceutical Association (KPA), the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KBPMA), and the Korea Pharmaceutical Distribution Association (KPDA).

KIPPA is a leading research center, which aims to promote public health through the development of policy regarding the rational use of medicines, pharmacy education, pharmacy practice, pharmaceutical industry, and pharmaceutical supply and distribution. In particular, we begin to develop ¡®a community pharmacy model as a health promotion center for community members¡¯. We are collecting and analysing big data accordingly to develop pharmacy-based policies, which pursue maximised pharmacy practice for all the Koreans.

In consequence, KIPPA will consistently implement research tailored to the promotion of health in the nation and worldwide. We kindly ask for supports from our fellow pharmacists, public and associations.

If you have any further enquiries about the institute or research in English, please contact us via e-mail (kippa.org@gmail.com).

Thank you.

Office Address
3FL, 194, Hyoryeong-ro, Seocho-gu, Seoul, Repbulic of Korea

ÇöÀçÀ§Ä¡ : Home : ¾Ë¸²¸¶´ç : ¿¬±¸¼Ò ´º½º
   
¾Ë¸²¸¶´ç
°øÁö»çÇ×
º¸µµÀÚ·á
ÀÎÀçä¿ë
 
 
Á¦   ¸ñ [´ëÇѾà»çÀú³Î] ÀǾàǰ ¾ÈÀü»ç¿ë ±³À° 'µµ¿òµÆ´Ù' 98%
³»   ¿ë

ÀǾàǰ ¾ÈÀü»ç¿ë ±³À° 'µµ¿òµÆ´Ù' 98%

ºÏÇÑÀÌÅ»ÁֹΠÆ÷Ä¿½º±×·ì ÀÎÅÍºä °á°ú ¹× 2019³â ¾à ¹Ù¸£°Ô ¾Ë±â <4>


Âü¿© ¿¬±¸¿ø Á¤½Â¿¬ ¼±ÀÓ¿¬±¸¿ø/Á¤µ¿¿í ºÎ¼±ÀÓ¿¬±¸¿ø
ÆíÁý ÀÓÀ翵 ½ÇÀå/ÀÌÁÖÇÏ ÁÖÀÓ¿¬±¸¿ø

ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò´Â ´ëÇѾà»çȸÀÇ '¾à¹Ù·Î¾²±â¿îµ¿º»ºÎ'°¡ ÁøÇàÇÑ ½ÄǰÀǾàǰ¾ÈÀüó ¹ßÁÖ ¿ë¿ª »ç¾÷ÀΠ¡®2020³â ¾à¹Ù¸£°Ô¾Ë±â ±³À°»ç¾÷¡®ÀÇ Æò°¡¸¦ ÁøÇàÇß´Ù. À̴ 2018, 2019³â¿¡ À̾à»çȸÀÇ ¿ë¿ªÀ¸·Î ¼¼¹øÂ°·Î ÁøÇàµÈ »ç¾÷(Æò°¡)ÀÌ´Ù. 2019³â Àå¾ÖÀΠ¹× Àå¾ÖÀΠ´ã´ç ±³»ç¸¦ ´ë»óÀ¸·Î ÁøÇàÇß´ø Ãë¾à°èÃþ ½Ã¹ü±³À°¿¡ À̾î 2020³â¿¡´Â ºÏÇÑÀÌÅ»ÁÖ¹ÎÀ» Ãë¾à°èÃþ ½Ã¹ü±³À° ´ë»óÀ¸·Î ¼±Á¤ÇØ À̵鿡°Ô ÀǾàǰ »ç¿ë ±³À°À» ½ÃÇàÇϱ⠾ռ­ Æ÷Ä¿½º±×·ìÀÎÅͺ並 ÁøÇàÇß´Ù.

2020³â 9¿ù ±âÁØ, Çѱ¹¿¡ ÀÔ±¹ÇÑ ºÏÇÑÀÌÅ»ÁÖ¹ÎÀº ÃÑ 3¸¸ 3718¸íÀÌ´Ù. 2000³â´ë ÀÌÈÄ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇØ 2003~2011³â¿¡´Â ¿¬°£ ÀÔ±¹ ÀοøÀÌ 2000¸í~3000¸í ¼öÁØ¿¡ À̸£·¶À¸³ª, 2012³â ÀÌÈÄ ÀÔ±¹ ÀοøÀÌ Á¡Â÷ ÁÙ¾îµé¾î ¿¬°£ Æò±Õ 1300¸í´ë·Î °¨¼ÒÇß°í, 2019³âµµ¿¡´Â 1047¸í ÀÔ±¹Çß´Ù. ÃÖ±Ù Äڷγª19ÀÇ ¿µÇâÀ¸·Î ÀÎÇÑ Å»ºÏ À̵¿ °æ·Î ±¹°¡ÀÇ ±¹°æ Æó¼â µîÀÇ ¿øÀÎÀ¸·Î ±× ¼ö´Â Å©°Ô °¨¼ÒÇϰí Àִ Ãß¼¼ÀÌ´Ù. ÇÏÁö¸¸ Äڷγª19 ÆÒµ¥¹ÍÀÌ ³¡³­ ÀÌÈÄ ¶Ç ±× ¼ö´Â Å©°Ô Áõ°¡ÇÒ ¼ö ÀÖ´Ù. Çѱ¹¿¡ Á¤ÂøÇÑ ÀÌÈÄ ºÏÇÑÀÌÅ»ÁÖ¹ÎÀÇ ÀÇ·á ¼­ºñ½º À̿령נÀǾàǰÀÇ º¹¿ë ÇàŰ¡ ±âÁ¸ÀÇ ±¹¹Î°ú´Â ´Ù¸£´Ù´Â Á¡ÀÌ º¸°íµÇ°í ÀÖ´Ù. ÀÌ¿¡ º» ¿¬±¸¼Ò´Â À̵éÀÇ °ú°Å ¹× ÇöÀçÀÇ ÀǾàǰ¿¡ ´ëÇÑ ÀνĠ¹× »ç¿ë ÇöȲÀ» ÆÄ¾ÇÇϰí À̸¦ Åä´ë·Î À̵éÀÇ Çʿ信 ºÎÇÕÇÑ ¸ÂÃãÇü ÀǾàǰ »ç¿ë ±³À°À» Á¦°øÇϴ °ÍÀ» ¸ñÇ¥·Î Æ÷Ä¿½º±×·ìÀÎÅͺ並 ÁøÇàÇß´Ù. 

ÀÌ¿¡ ¸ÕÀú ºÏÇÑÀÌÅ»ÁֹΠ´ë»ó Æ÷Ä¿½º±×·ì ÀÎÅͺ䠰á°ú¿Í ÇÔ²² À̵éÀ» À§ÇÑ ÀǾàǰ ¾ÈÀü»ç¿ë ±³À°¿¡ Æ÷ÇԵǾî¾ß ÇÒ °ÍÀ¸·Î Á¦¾ÈÇß´ø ³»¿ëÀ» ¼Ò°³ÇϰíÀÚ ÇÑ´Ù. ¸¶Áö¸·À¸·Î À̵éÀ» ´ë»óÀ¸·Î ÁøÇàÇß´ø ÀǾàǰ ¾ÈÀü»ç¿ë ±³À°ÀÇ Æò°¡ °á°ú¸¦ ÅëÇØ ºÏÇÑÀÌÅ»ÁֹΠ´ë»ó ±³À° ¼öÇàÀÇ Àǹ̿͠³ª¾Æ°¥ ¹æÇâ¿¡ ´ëÇØ °íÂûÇØ º¸°íÀÚ ÇÑ´Ù.


<Áö³­È£¿¡ À̾>
³ª. ºÏÇÑÀÌÅ»ÁֹΠ´ë»ó ÀǾàǰ ¾ÈÀü»ç¿ë ±³À° Æò°¡
(1) ºÏÇÑÀÌÅ»ÁֹΠ´ë»ó ±³À° Æò°¡
ºÏÇÑÀÌÅ»ÁֹΠ´ë»ó ÀǾàǰ ¾ÈÀü»ç¿ë ±³À°Àº ÃÑ 6ȸ ÁøÇàµÆÀ¸¸ç, ÃÑ 47¸íÀÌ ±³À°¿¡ Âü¿©Çß´Ù. ±³À° ÀÌÈÄ ¼³¹®ÀÇ Çü½ÄÀ¸·Î Æò°¡¸¦ ÁøÇàÇß´Ù.

(2) ±³À° ´ë»óÀÚÀÇ ÀϹÝÀû Æ¯¼º
±³À° ´ë»óÀÚÀÇ ¼ºº°À» º¸¸é ¿©¼ºÀÇ ºñÀ²ÀÌ ¾à 70%·Î ³ô¾ÒÀ¸¸ç, ¿¬·É´ë´Â 40´ë, 50´ëÀÇ Âü¿©°¡ ³ôÀ½À» ¾Ë ¼ö ÀÖ´Ù. ¶ÇÇÑ, ±³À° Âü¿©ÀÚÀÇ 68%°¡ ÀÌÀü¿¡ ÀǾàǰ ¾ÈÀü»ç¿ë ±³À° °æÇèÀÌ ¾ø´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù.


(3) ±³À° ¸¸Á·µµ
ºÏÇÑÀÌÅ»ÁֹΠ´ë»ó ¾à ¹Ù¸£°Ô ¾Ë±â ±³À°(½Ã¹ü) Âü¿©ÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ ±³À° ¸¸Á·µµ Á¶»ç °á°ú¸¦ º¸¸é ´ÙÀ½°ú °°´Ù. 


¸ÕÀú ±³À°ÀÇ µµ¿ò Á¤µµ ¹× ±³À°ÀÇ ÀÌÇØµµ µîÀ» ÆÄ¾ÇÇß´Ù. ±× °á°ú ±³À° ³»¿ëÀÌ ÀÌÇØÇϱ⠽±´Ù°í ÀÀ´äÇÑ ºñÀ²Àº ¾à 96%¿´À¸¸ç, Âü¿©ÇÑ ÀǾàǰ ¾ÈÀü»ç¿ë ±³À°ÀÌ µµ¿òÀÌ µÆ´Ù°í ÀÀ´äÇÑ ºñÀ²µµ ¾à 98%·Î ³ªÅ¸³µ´Ù. 

¶ÇÇÑ ÀǾàǰ °ü·Ã ¿ë¾î ÀÌÇØÀÇ Á¤µµ´Â ÀÀ´äÀÚÀÇ ¾à 98%°¡ ¸Å¿ì ½±°Å³ª ½±´Ù°í ÀÀ´äÇß´Ù. ´ÙÀ½À¸·Î ±³À°¿¡ Âü¿©ÇÑ ÀÀ´äÀÚÀÇ ¾à 98%°¡ ±³À°ÀÇ ³»¿ëÀÌ °¡Á·À̳ª ÁöÀο¡°Ô ¸Å¿ì µµ¿òÀÌ µÇ°Å³ª µµ¿òÀÌ µÉ ¼ö ÀÖÀ» °ÍÀ̶ó°í ÀÀ´äÇß´Ù.

ÀÌ·¯ÇÑ °á°ú´Â ÀǾàǰ ¾ÈÀü»ç¿ë ±³À°¿¡ ¾Õ¼­ À̵éÀÇ ÀǾàǰ¿¡ ´ëÇÑ ÀνĠ¹× »ç¿ë °æÇèÀ» ÆÄ¾ÇÇϰí À̸¦ Åä´ë·Î ±³À° ³»¿ëÀÌ °³¹ßµÆ±â ¶§¹®ÀÏ °ÍÀ¸·Î º¼ ¼ö ÀÖ´Ù. <´ÙÀ½È£¿¡ °è¼Ó>


[±â»çÃâó] https://www.kpanews.co.kr/academy/show.asp?page=1&search_cate=8&idx=713

 

¹øÈ£ ÷ºÎ Á¦¸ñ ÀÛ¼ºÀÚ ÀÛ¼ºÀÏ Á¶È¸
129 [´ëÇѾà»çÀú³Î]°ø°ø½É¾ß¾à±¹, »ç¾÷ È®´ë À§ÇØ ¿î¿µ¡¤ÆíÀÇ °³¼± ÇÊ¿ä ÀÌÁÖÇÏ 2021-09-23 900
128 [´ëÇѾà»çÀú³Î]½É¾ß½Ã°£ ¾à±¹ ÀÌ¿ë '¸¸Á·ÇÑ´Ù' 93.5% ÀÌÁÖÇÏ 2021-09-23 780
127 [´ëÇѾà»çÀú³Î]¿µ±¹, OHH ¼­ºñ½º ÀϹݾࡤÀü¹®¾à ³ª´² Á¦°ø ÀÌÁÖÇÏ 2021-09-23 758
126 [´ëÇѾà»çÀú³Î]È£ÁÖ ¹ãÀ» ¹àÈ÷´Â 'Supercare' ¾à±¹ ÀÌÁÖÇÏ 2021-09-23 764
125 [ÀǾàǰÁ¤Ã¥¸®Æ÷Æ®]ÀÀ´äÀÚ 94.3% µµÀÔ Âù¼º¡¦Àü¹®Àû »ó´ã Àý½Ç ÀÌÁÖÇÏ 2021-09-23 250
124 [´ëÇѾà»çÀú³Î] ¾à ±¸ÀÔ ½Ã ¾à»ç¿Í »ó´ãÀÌ Áß¿ä 85% ÀÌÁö¿¬ 2021-08-10 520
123 [´ëÇѾà»çÀú³Î] ÀǾàǰ ¾ÈÀü»ç¿ë ±³À° 'µµ¿òµÆ´Ù' 98% ÀÌÁö¿¬ 2021-08-02 460
122 [´ëÇѾà»çÀú³Î] ¾ÆÆí ÇÔÀ¯ 'Á¤ÅëÆí' ÅëÁõ ¸¸º´ÅëÄ¡¾àó·³ »ç¿ë ÀÌÁö¿¬ 2021-08-02 506
121 [´ëÇѾà»çÀú³Î] ºÏÇÑÀÌÅ»ÁֹΠó¹æÀǾàǰ È¿°ú ½Å·Ú ´õ ³ô¾Æ ÀÌÁö¿¬ 2021-07-21 448
120 [´ëÇѾà»çÀú³Î] ºÏÇÑÀÌÅ»ÁֹΠÀǾàǰ Àνİú »ç¿ë ÇöȲÀº? ÀÌÁö¿¬ 2021-07-14 390
119 [´ëÇѾà»çÀú³Î] "ºÎÀÛ¿ë °æÇè 98% Áõ»ó ½Å°í¾ÈÇØ" ºÒ°¨Áõ ½É°¢ ÀÌÁö¿¬ 2021-07-07 464
118 [´ëÇѾà»çÀú³Î] ¾ÈÀü»óºñÀǾàǰ ±¸ÀÔ ¿äÀÏ ÁÖ¸» '50.3%' Â÷Áö ÀÌÁö¿¬ 2021-06-29 452
117 [´ëÇѾà»çÀú³Î] ±¹¹Î 90% 1³â°£ ÆíÀÇÁ¡ »óºñ¾à ÃÖ´ë 5ȸ ±¸ÀÔ ÀÌÁö¿¬ 2021-06-22 486
116 [´ëÇѾà»çÀú³Î] ÆíÀÇÁ¡ ºøÀå Ç®¸®ÀÚ ½ñ¾ÆÁø °¨±â¾à¡¤ÁøÅëÁ¦ ÀÌÁö¿¬ 2021-06-16 433
115 [´ëÇѾà»çÀú³Î] Áö¿ª¾à±¹ '»ý¸íÁöÅ´ÀÌ' ¿ªÇÒ ¼öÇà °ü½É ³ôÇû´Ù ÀÌÁö¿¬ 2021-06-09 441

ÀÌÀü 10ÆäÀÌÁö [1]  [2]  [3]  [4]  [5]  [6]  [7]  [8]  [9]  ´ÙÀ½ 10ÆäÀÌÁö

 
 

¼­¿ï ¼­Ãʱ¸ È¿·É·Î194, 3Ãþ (Àç)ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò TEL : 02) 3474-5301 / FAX : 02)3474-5306

COPYRIGHT (C) 2006 KOREA INSTITUTE FOR PHARMACEUTICAL POLICY AFFAIRS ALL RIGHTS RESERVED. FOR MORE INFORMATION MAL kippa.org@gmail.com

±âºÎ±Ý ¾È³»